Literature DB >> 15774714

Chronic estrogen sensitizes a subset of mechanosensitive afferents innervating the uterine cervix.

Baogang Liu1, James C Eisenach, Chuanyao Tong.   

Abstract

Estrogen increases reflex nocifensive responses to distension of the uterus and the urinary bladder, but estrogen's effects on afferent response to distension of the uterine cervix, the site of obstetric and some gynecologic pain, has not been studied. Here, single fiber recording of hypogastric nerve responses to uterine cervical distension were obtained from ovariectomized (OVX) rats and OVX rats treated with estrogen (ES). Spontaneous activity was greater in the ES group (13 of 24 units; 54%) than in the OVX group (6 of 27 units; 22%). ES differentially altered the response of low- and high-threshold units to distension. For high-threshold units, firing frequency was increased two- to fourfold with 60-100 gm distension in ES compared with OVX groups (P < 0.05). In contrast, the response of low-threshold units to distension was not altered by ES. About one-half of units tested in each group responded to a temperature increase from 35 to 49 degrees C. A greater proportion of thermosensitive units were also mechanosensitive in the ES group (7 of 8 afferents, 88%) than in the OVX group (5 of 11 afferents, 45%). Acute application of ES in OVX rats failed to evoke or increase distension-induced responses. These data show the polymodal nature of afferent fibers innervating the uterine cervix. Increased spontaneous activity with ES may play a part in remodeling of the cervical tissue, whereas selective sensitization of high-threshold units by ES might underlie increased pain responses to cervical distension. Failure of acute ES treatment to mimic this suggests a genomic effect.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15774714     DOI: 10.1152/jn.01012.2004

Source DB:  PubMed          Journal:  J Neurophysiol        ISSN: 0022-3077            Impact factor:   2.714


  8 in total

1.  A clinically relevant animal model of temporomandibular disorder and irritable bowel syndrome comorbidity.

Authors:  Richard J Traub; Dong-Yuan Cao; Jane Karpowicz; Sangeeta Pandya; Yaping Ji; Susan G Dorsey; Dean Dessem
Journal:  J Pain       Date:  2014-06-26       Impact factor: 5.820

2.  Circulating sex steroids and bladder pain sensitivity in dysmenorrhea.

Authors:  Kevin M Hellman; Folabomi A Oladosu; Ellen F Garrison; Genevieve E Roth; Katlyn E Dillane; Frank F Tu
Journal:  Mol Pain       Date:  2021 Jan-Dec       Impact factor: 3.395

Review 3.  Sex differences and hormonal modulation of deep tissue pain.

Authors:  Richard J Traub; Yaping Ji
Journal:  Front Neuroendocrinol       Date:  2013-07-17       Impact factor: 8.606

4.  Pregnancy increases excitability of mechanosensitive afferents innervating the uterine cervix.

Authors:  Baogang Liu; Chuanyao Tong; James C Eisenach
Journal:  Anesthesiology       Date:  2008-06       Impact factor: 7.892

5.  Estrogen receptor β activation is antinociceptive in a model of visceral pain in the rat.

Authors:  Dong-Yuan Cao; Yaping Ji; Bin Tang; Richard J Traub
Journal:  J Pain       Date:  2012-06-13       Impact factor: 5.820

6.  Estrogen metabolites increase nociceptor hyperactivity in a mouse model of uterine pain.

Authors:  Zili Xie; Jing Feng; Tao Cai; Ronald McCarthy; Mark D Eschbach; Yuhui Wang; Yonghui Zhao; Zhihua Yi; Kaikai Zang; Yi Yuan; Xueming Hu; Fengxian Li; Qin Liu; Aditi Das; Sarah K England; Hongzhen Hu
Journal:  JCI Insight       Date:  2022-05-23

7.  Pirt contributes to uterine contraction-induced pain in mice.

Authors:  Changming Wang; Zhongli Wang; Yan Yang; Chan Zhu; Guanyi Wu; Guang Yu; Tunyu Jian; Niuniu Yang; Hao Shi; Min Tang; Qian He; Lei Lan; Qin Liu; Yun Guan; Xinzhong Dong; Jinao Duan; Zongxiang Tang
Journal:  Mol Pain       Date:  2015-09-17       Impact factor: 3.395

8.  Resolution of pain after childbirth.

Authors:  James C Eisenach; Peter Pan; Richard M Smiley; Patricia Lavand'homme; Ruth Landau; Timothy T Houle
Journal:  Anesthesiology       Date:  2013-01       Impact factor: 8.986

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.